95 related articles for article (PubMed ID: 28103010)
1. A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo.
Crowe LB; Hughes PF; Alcorta DA; Osada T; Smith AP; Totzke J; Loiselle DR; Lutz ID; Gargesha M; Roy D; Roques J; Darr D; Lyerly HK; Spector NL; Haystead TAJ
ACS Chem Biol; 2017 Apr; 12(4):1047-1055. PubMed ID: 28103010
[TBL] [Abstract][Full Text] [Related]
2. Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo.
Stivarou T; Stellas D; Vartzi G; Thomaidou D; Patsavoudi E
Cancer Biol Ther; 2016 Aug; 17(8):799-812. PubMed ID: 27259689
[TBL] [Abstract][Full Text] [Related]
3. Detection and Analysis of Extracellular Hsp90 (eHsp90).
Cortes S; Baker-Williams AJ; Mollapour M; Bourboulia D
Methods Mol Biol; 2018; 1709():321-329. PubMed ID: 29177669
[TBL] [Abstract][Full Text] [Related]
4. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally.
Li W; Tsen F; Sahu D; Bhatia A; Chen M; Multhoff G; Woodley DT
Int Rev Cell Mol Biol; 2013; 303():203-35. PubMed ID: 23445811
[TBL] [Abstract][Full Text] [Related]
5. Emerging Roles of Extracellular Hsp90 in Cancer.
Wong DS; Jay DG
Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
[TBL] [Abstract][Full Text] [Related]
6. Secreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity.
Nolan KD; Kaur J; Isaacs JS
Oncotarget; 2017 Mar; 8(12):19323-19341. PubMed ID: 28038472
[TBL] [Abstract][Full Text] [Related]
7. Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens.
Crouch B; Murphy H; Belonwu S; Martinez A; Gallagher J; Hall A; Soo MS; Lee M; Hughes P; Haystead T; Ramanujam N
Sci Rep; 2017 Dec; 7(1):17487. PubMed ID: 29235516
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Heat Shock Protein-90 (eHsp90): Everything You Need to Know.
Jay D; Luo Y; Li W
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883467
[TBL] [Abstract][Full Text] [Related]
9. Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.
Barrott JJ; Hughes PF; Osada T; Yang XY; Hartman ZC; Loiselle DR; Spector NL; Neckers L; Rajaram N; Hu F; Ramanujam N; Vaidyanathan G; Zalutsky MR; Lyerly HK; Haystead TA
Chem Biol; 2013 Sep; 20(9):1187-97. PubMed ID: 24035283
[TBL] [Abstract][Full Text] [Related]
10. Methods to Assess the Impact of Hsp90 Chaperone Function on Extracellular Client MMP2 Activity.
Votra SD; Alsalih D; Bourboulia D
Methods Mol Biol; 2023; 2693():221-232. PubMed ID: 37540438
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors.
Devarakonda CV; Kita D; Phoenix KN; Claffey KP
BMC Cancer; 2015 Sep; 15():614. PubMed ID: 26334999
[TBL] [Abstract][Full Text] [Related]
12. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
13. Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling.
Daoud A; Gopal U; Kaur J; Isaacs JS
Oncotarget; 2017 Dec; 8(63):106807-106819. PubMed ID: 29290990
[TBL] [Abstract][Full Text] [Related]
14. In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.
Ardeshirpour Y; Chernomordik V; Hassan M; Zielinski R; Capala J; Gandjbakhche A
Clin Cancer Res; 2014 Jul; 20(13):3531-9. PubMed ID: 24671949
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
16. Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells.
Oura J; Tamura Y; Kamiguchi K; Kutomi G; Sahara H; Torigoe T; Himi T; Sato N
Int Immunol; 2011 Apr; 23(4):223-37. PubMed ID: 21421737
[TBL] [Abstract][Full Text] [Related]
17. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
18. The double-edged sword: conserved functions of extracellular hsp90 in wound healing and cancer.
Hance MW; Nolan KD; Isaacs JS
Cancers (Basel); 2014 May; 6(2):1065-97. PubMed ID: 24805867
[TBL] [Abstract][Full Text] [Related]
19. An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein.
McCready J; Wong DS; Burlison JA; Ying W; Jay DG
Cancers (Basel); 2014 Apr; 6(2):1031-46. PubMed ID: 24785146
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
